Jeff Yass’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$244K Sell
50,100
-47,300
-49% -$273K ﹤0.01% 11465
2026
Q2
$663K Buy
97,400
+86,300
+777% +$511K ﹤0.01% 9237
2026
Q1
$49.6K Sell
11,100
-74,400
-87% -$346K ﹤0.01% 12637
2025
Q4
$470K Buy
+85,500
New +$415K ﹤0.01% 8931
2024
Q4
– Sell
-10,700
Closed -$21.5K – 13247
2024
Q3
$21.5K Sell
10,700
-11,700
-52% -$25.7K ﹤0.01% 11617
2024
Q2
$50.2K Buy
+22,400
New +$65.2K ﹤0.01% 11410
2024
Q1
– Sell
-32,800
Closed -$58.1K – 13347
2023
Q4
$58.1K Sell
32,800
-2,500
-7% -$4.98K ﹤0.01% 11654
2023
Q3
$112K Buy
+35,300
New +$65.9K ﹤0.01% 10829
2023
Q1
– Sell
-12,700
Closed -$28.7K – 13514
2022
Q4
$28.7K Buy
+12,700
New +$25.7K ﹤0.01% 11637

Other funds holding TSHA

Jeff Yass's TSHA Position: Q3 2026 in Review

Jeff Yass increased its Taysha Gene Therapies (TSHA) stake by 2,449% in Q3 2026, buying an estimated $3.83M and bringing the position to 692,416 shares worth $3.37M. The position accounts for ﹤0.01% of the portfolio, ranked #5177.

Jeff Yass first reported a position in TSHA in Q2 2022 and has held it in 16 quarters since. The position peaked at $3.76M in Q1 2024. 203 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Jeff Yass held 692,416 shares of Taysha Gene Therapies worth $3.37M as of Q3 2026.
  • Jeff Yass bought 665,252 Taysha Gene Therapies shares in Q3 2026, an estimated $3.83M.
  • Taysha Gene Therapies made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #5177 holding.
  • Jeff Yass first reported a position in Taysha Gene Therapies in Q2 2022 and has held it in 16 quarters since.
  • Jeff Yass's Taysha Gene Therapies position peaked at $3.76M in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.